What do systematic reviews say?

Antifungal drugs not absorbed from GI tract vs placebo or no treatment

Antifungal drugs not absorbed from GI tract showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.1 [0.01, 1.75]
  2 studies · 71 participants
  GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 2.27 [0.23, 22.56]
  1 study · 32 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.65 [0.37, 1.14]
  6 studies · 1041 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in good compliance compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.06 [0.89, 1.27]
  2 studies · 615 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.44 [0.14, 15.43]
  3 studies · 718 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Pilocarpine vs placebo

• Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy 2015 · Cochrane All outcomes
  Both studies assessed oral discomfort and dysphonia (Johnson 1993; LeVeque 1993); pilocarpine reported to improve associated symptoms of salivary gland dysfunction (oral discomfort, dysphonia). No pooled data.
  2 studies · 278 participants
  GRADE not reported

Pilocarpine vs Artificial saliva

• Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy 2015 · Cochrane All outcomes
  Davies 1994 assessed dysgeusia and dysphagia; pilocarpine reported more effective than mucin-based artificial saliva for dysgeusia. No pooled data.
  1 study · 20 participants
  GRADE not reported

Itraconazole vs Fluconazole

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  2 studies, 232 participants; effect not estimable
  2 studies · 232 participants
  GRADE not reported